Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility | Zendy

Jayan Nagendran | Zendy; Stephen L. Archer | Zendy; Daniel Soliman | Zendy; Vikram Gurtu | Zendy; Rohit Moudgil | Zendy; Alois Haromy | Zendy; Chantal St. Aubin | Zendy; Linda Webster | Zendy; Ivan M. Rebeyka | Zendy; David B. Ross | Zendy; Peter E. Light | Zendy; Jason R.B. Dyck | Zendy; Evangelos D. Michelakis | Zendy

Open Access

Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

Author(s) -

Jayan Nagendran,

Stephen L. Archer,

Daniel Soliman,

Vikram Gurtu,

Rohit Moudgil,

Alois Haromy,

Chantal St. Aubin,

Linda Webster,

Ivan M. Rebeyka,

David B. Ross,

Peter E. Light,

Jason R.B. Dyck,

Evangelos D. Michelakis

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.655266

Subject(s) - contractility , medicine , sildenafil , ventricle , pulmonary hypertension , phosphodiesterase 3 , cgmp specific phosphodiesterase type 5 , amrinone , afterload , cardiology , inotrope , endocrinology , phosphodiesterase , protein kinase a , kinase , chemistry , biology , microbiology and biotechnology , biochemistry , enzyme

Sildenafil was recently approved for the treatment of pulmonary arterial hypertension. The beneficial effects of phosphodiesterase type 5 (PDE5) inhibitors in pulmonary arterial hypertension are thought to result from relatively selective vasodilatory and antiproliferative effects on the pulmonary vasculature and, on the basis of early data showing lack of significant PDE5 expression in the normal heart, are thought to spare the myocardium.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research